Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Tel Aviv University

Headquarters: Tel Aviv, Israel
Year Founded: 1956
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Feb 15, 2025
Discovery & Translation

Science Spotlight: Using HIV to help allogeneic CAR T cells evade immune attack

BioCentury’s roundup of translational innovations also includes a human hypothalamus atlas from Novo and collaborators, and four papers with links to newcos
BioCentury | May 3, 2024
Discovery & Translation

CAR T cells: Cancer, autoimmunity, and beyond?

ASGCT abstracts highlight applications for CAR Ts outside of cancer
BioCentury | Mar 7, 2024
Management Tracks

Sandoz names new CFO, board nominations

Plus: McKinsey vet Littlejohns becomes Velsera’s CEO and updates from MBrace, Fibrobiologics, NeoVac and Mithra
BioCentury | Jan 27, 2024
Discovery & Translation

Genentech’s i-shaped Abs; a bispecific dendritic-T cell engager and more

BioCentury’s roundup of translational innovations
BioCentury | Mar 31, 2023
Deals

March 30 Quick Takes: Scynexis deal gives GSK another anti-infective

Plus: AstraZeneca in-licenses CLDN18.2 asset from China’s KYM, updates from newly public biotechs Apollomics and GI Innovation and more 
BioCentury | Nov 5, 2022
Discovery & Translation

A gene therapy to drive hyperexcitable neurons back to baseline; plus a conditionally active IL-2 and more

BioCentury’s roundup of translational news
BioCentury | Jul 1, 2022
Discovery & Translation

T cell aneuploidy after CRISPR TRAC editing; plus Poseida, Cellectis and more

BioCentury’s roundup of translational news
BioCentury | Jun 11, 2022
Discovery & Translation

In vivo B cell engineering to produce anti-HIV antibodies; plus Ovid, Stealth and more

BioCentury’s roundup of translational news
Items per page:
1 - 10 of 79